Prognostic Markers for Thrombotic Events in Cancer Patients
Author Information
Author(s): Emilly de Assis Machado, Marcelo Gerardin Poirot, Alberto Schanaider
Primary Institution: Universidade Federal do Rio de Janeiro
Hypothesis
Can plasma circulation tumor DNA and thrombin-antithrombin complex levels predict thrombotic events and death in patients with gastric or colorectal adenocarcinomas?
Conclusion
Thrombin-antithrombin complex is a marker for thrombosis in patients with colorectal and gastric adenocarcinomas, and prophylactic anticoagulation is recommended when certain risk factors are present.
Supporting Evidence
- 16% of patients experienced thrombosis during treatment.
- Patients with TAT levels greater than 0.53 ng/ml had a five-times higher risk of thrombosis.
- Lower Karnofsky Performance Status was a risk factor for thrombosis.
Takeaway
This study found that certain blood tests can help doctors know if cancer patients are at risk for blood clots, which can be dangerous.
Methodology
The study included 82 patients divided into three groups, with blood tests conducted to measure various factors related to thrombosis.
Potential Biases
Potential biases may arise from the observational nature of the study and the specific patient population.
Limitations
The study had a limited sample size and was conducted at a single institution.
Participant Demographics
The sample included 62 patients with colorectal and gastric adenocarcinomas, with a near-equal gender distribution.
Statistical Information
P-Value
p<0.001 for comparisons with control group
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website